Structure-based design of anticancer drugs based on β-elemene: Research foundations and development potential.

Area of Science:

• Pharmacology
• Drug Discovery
• Computational Chemistry

Background:

• Beta-elemene is a bioactive compound from traditional Chinese medicine used in cancer therapy.
• Optimization of beta-elemene's physicochemical properties and elucidation of its anticancer mechanisms are needed.
• Structure-based drug design (SBDD) and computational methods are crucial in modern drug development.

Purpose of the Study:

• To identify potential molecular targets of beta-elemene using computational approaches.
• To explore the application of AI-driven molecular generation in optimizing beta-elemene for enhanced anticancer efficacy.
• To lay the groundwork for rational drug design integrating TCM with modern techniques.

Main Methods:

• Comprehensive review of molecular biology studies.
• Virtual molecular docking experiments.
• Examination of AI-based de novo molecular generation and lead optimization models.

Main Results:

• Methyltransferase-like 3 (METTL3) was identified as a potential molecular target of beta-elemene.
• Ligand-receptor interactions were analyzed to explore potential strategies for developing novel anticancer derivatives.
• The study explored AI models for de novo molecular generation and lead optimization.

Conclusions:

• METTL3 is a potential therapeutic target for beta-elemene in cancer treatment.
• Integrating rational drug design with beta-elemene can enhance the efficacy of traditional Chinese medicine.
• AI-based approaches offer promising strategies for developing more potent anticancer derivatives of beta-elemene.